Marshall, Gerstein & Borun Continues Expansion of Biotechnology Practice with Addition of Thomas Wrona, Ph.D.

June 3, 2015

Marshall, Gerstein & Borun LLP announced today that Thomas J. Wrona, Ph.D., has re-joined the Firm as Special Counsel in the Firm’s growing Biotechnology practice. Dr. Wrona most recently served as Senior Counsel at Amgen Inc.

Tom has nearly two decades of intellectual property experience working both in-house and in private practice, including previous experience with the Firm. While at Amgen, he served as intellectual property due diligence lead on dozens of in-licensing, partnership, and M&A opportunities. Moreover, he developed the global IP strategy and managed the IP portfolios of marketed, clinical, and pre-clinical therapeutic molecules. He has extensive IP experience in a broad range of biotechnologies including antibody engineering, oncolytic viruses, chimeric antigen T cells, and therapeutic antisense molecules.

"Tom is an ideal addition to our Biotechnology team," said Heather Kissling, chair of the Biotechnology group. “His extensive experience as in-house counsel makes him well-versed in understanding the pressures of in-house IP groups, and his ability to understand IP strategy and maximize the value of patent portfolios will be invaluable to our biotechnology clients.”

Dr. Wrona earned his J.D., cum laude, and his Certificate of Intellectual Property Law from The John Marshall Law School, his Ph.D. in Microbiology from The University of Texas at Austin, and his B.S. in Microbiology from The University of Illinois, Urbana-Champaign. He is a member of the State Bar of Illinois, and a registered patent attorney with the United States Patent and Trademark Office.

Marshall, Gerstein & Borun’s large biotechnology practice group includes lawyers, patent agents, and technical specialists experienced in a variety of technical disciplines, including DNA, RNA, protein, and antibody therapeutics; immunotherapy; diagnostics; plant biotechnology; industrial biotechnology and research platforms; nanotechnology; and interdisciplinary inventions. The team handles all variety of biotechnology IP matters, including patent litigation and prosecution; counseling; agreements and transactions; and pharmaceutical trademarks. The vast majority of team members have advanced scientific degrees or have biotechnology industry or research experience.